PL1912626T3 - Postaci użytkowe o polepszonej biodostępności - Google Patents

Postaci użytkowe o polepszonej biodostępności

Info

Publication number
PL1912626T3
PL1912626T3 PL06776679.0T PL06776679T PL1912626T3 PL 1912626 T3 PL1912626 T3 PL 1912626T3 PL 06776679 T PL06776679 T PL 06776679T PL 1912626 T3 PL1912626 T3 PL 1912626T3
Authority
PL
Poland
Prior art keywords
dosage forms
improved bioavailability
bioavailability
improved
dosage
Prior art date
Application number
PL06776679.0T
Other languages
English (en)
Inventor
Gunther Berndl
Matthias Degenhardt
Markus Mägerlein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL1912626T3 publication Critical patent/PL1912626T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06776679.0T 2005-08-08 2006-08-08 Postaci użytkowe o polepszonej biodostępności PL1912626T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59581805P 2005-08-08 2005-08-08

Publications (1)

Publication Number Publication Date
PL1912626T3 true PL1912626T3 (pl) 2016-10-31

Family

ID=37122088

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06776679.0T PL1912626T3 (pl) 2005-08-08 2006-08-08 Postaci użytkowe o polepszonej biodostępności

Country Status (9)

Country Link
US (2) US20090028938A1 (pl)
EP (1) EP1912626B1 (pl)
JP (1) JP2009504590A (pl)
CA (1) CA2618264C (pl)
DK (1) DK1912626T3 (pl)
ES (1) ES2576633T3 (pl)
PL (1) PL1912626T3 (pl)
PT (1) PT1912626T (pl)
WO (1) WO2007017249A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CN101111245A (zh) 2005-01-27 2008-01-23 阿雷姆贝克有限公司 左乙拉西坦延长释放制剂
WO2007014393A2 (en) * 2005-07-28 2007-02-01 Isp Investments Inc. Amorphous efavirenz and the production thereof
US8486456B2 (en) 2005-08-08 2013-07-16 Abbott Gmbh & Co., Kg Itraconazole compositions with improved bioavailability
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
CA2714190C (en) * 2008-02-28 2018-01-16 Nishanth Gopinathan Tablets and preparation thereof
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
US20140024723A1 (en) * 2012-07-17 2014-01-23 Dow Global Technologies Llc Composition comprising an organic liquid diluent and a specific hydroxypropyl methylcellulose
BR112014031471B1 (pt) 2012-07-17 2020-12-01 Dow Global Technologies Llc composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US9980946B1 (en) * 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
US11517548B2 (en) * 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
NZ249494A (en) 1992-03-18 1996-04-26 Janssen Pharmaceutica Nv Itraconazole and saperconazole stereoisomers; pharmaceutical compositions
IL123654A (en) * 1995-11-23 2001-08-08 Janssen Pharmaceutica Nv Process for the preparation of solid mixtures of cyclodextrins and pharmaceutical preparations containing such solid mixtures
CA2240161C (en) * 1996-05-20 2005-05-24 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
DE69804994D1 (de) * 1997-11-03 2002-05-23 Janssen Pharmaceutica Nv Arzneimittel enthaltend lipidsenkende verbindungen
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
WO2002024168A1 (fr) * 2000-09-25 2002-03-28 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide medicinale
CN101480384A (zh) * 2002-12-17 2009-07-15 阿伯特有限及两合公司 包含非诺贝酸、其生理可接受的盐或衍生物的制剂
CA2509688A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8486456B2 (en) * 2005-08-08 2013-07-16 Abbott Gmbh & Co., Kg Itraconazole compositions with improved bioavailability

Also Published As

Publication number Publication date
DK1912626T3 (en) 2016-08-01
ES2576633T3 (es) 2016-07-08
PT1912626T (pt) 2016-07-20
CA2618264C (en) 2015-11-24
CA2618264A1 (en) 2007-02-15
JP2009504590A (ja) 2009-02-05
WO2007017249A1 (en) 2007-02-15
US9060936B2 (en) 2015-06-23
US20110311595A1 (en) 2011-12-22
EP1912626B1 (en) 2016-04-13
EP1912626A1 (en) 2008-04-23
US20090028938A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
IL251539A0 (en) Single pharmaceutical dosage form
PT1912626T (pt) Formas farmacêuticas com biodisponibilidade melhorada
GB0501999D0 (en) Pharmaceutical compounds
GB0520657D0 (en) Pharmaceutical compounds
GB0520656D0 (en) Pharmaceutical compounds
GB0508306D0 (en) Nicotine dosage forms
AP2007004099A0 (en) Alcohol resistant dosage forms
AP2008004533A0 (en) Pharmaceutical combination
GB0513984D0 (en) Dosage form
ZA200800368B (en) New pharmaceutical compounds
GB0427455D0 (en) Dosage forms
EP1929085A4 (en) FEEDING DEVICE
GB0512643D0 (en) Pharmaceutical compounds
ZA200804666B (en) Pharmaceutical combination
GB0512246D0 (en) Novel pharmaceutical
TWI372053B (en) Combination drug
ZA200705612B (en) Pharmaceutical compounds
GB0501475D0 (en) Pharmaceutical compounds
GB0522989D0 (en) Dosage form
GB0502055D0 (en) Pharmaceutical compounds
GB0516790D0 (en) Pharmaceutical compounds
GB0501480D0 (en) Pharmaceutical compounds
GB0501729D0 (en) Pharmaceutical compounds
GB0512681D0 (en) Pharmaceutical compounds
GB0516167D0 (en) Pharmaceutical compounds